InvestLog
PRFX PRF Technologies Ltd. logo

PRFX PRF Technologies Ltd.

Healthcare
$1.49+2.76%ClosedMarket Cap: $119,993

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.01

P/S

0.00

EV/EBITDA

0.97

DCF Value

$6.42

FCF Yield

-3309.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-47.0%

ROA

-26.7%

ROIC

-33.9%

Financials

View All
PeriodRevenueNet IncomeEPS
FY null$17.0K$-4.8M$—
Q2 null$0.00$-1.2M$—
Q1 null$0.00$-1.2M$—
Q4 null$0.00$-885.0K$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy0 Buy1 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Cohen-Arazi Efraimdirector, officer: Interim CEO
SellWed Mar 18
Cohen-Arazi Efraimdirector, officer: Interim CEO
SellWed Mar 18
Cohen-Arazi Efraimdirector, officer: Interim CEO
SellWed Mar 18
Cohen-Arazi Efraimdirector, officer: Interim CEO
SellWed Mar 18
BARON ELLEN Sdirector
SellWed Mar 18

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

IL

Exchange

—

Beta

0.77

PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Peers

ATXI logoATXIDRMA logoDRMAELAB logoELABNCEL logoNCELNKGN logoNKGNPBM logoPBMUPC logoUPCVRAX logoVRAXWINT logoWINTXRTX logoXRTX